Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:3/26/2009

ontains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' ability to fund its operations on an ongoing basis, financing and strategic alternatives for the company, the status of the company's senior secured notes and potential partnering arrangements for certain of the company's programs. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the company's default on its senior secured notes, the right of the note holders to accelerate the obligations at any time, the company's potential need to seek protection under the provisions of the U.S. Bankruptcy Code in the event of an acceleration of the senior secured notes or otherwise and the resulting risk to the stockholders' receipt of any value for their shares; the company's need to raise additional funds; product sales and revenues; and the cost and results of product development and clinical trials. These and other risk factors are discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2008 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on March 26, 2009. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

                            JAZZ PHARMACEUTICALS, INC.
                       CONSOLIDATED STATEMENTS OF OPERATIONS
                     (In thousands, except per share amounts)
                                    (Unaudited)

                                        Three Mo
'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... organic compounds, which are mixed with animal feed to ... gain, and improve gut health and digestion. Amidst the ... eggs and meat across the globe, the need for ... aquaculture sectors is on the rise, thereby driving demand ...
(Date:9/30/2014)... of patients with bowel cancer for a genetic condition ... ovarian cancers, new research has found. , In a ... of Medicine and researchers from the University of Exeter,s ... screening programme for a genetic condition known as Lynch ... a caused by changes in genes which check the ...
(Date:9/30/2014)... research report published in the October 2014 issue of ... detection of cancer as easy as a simple blood test. ... not only detect some cancers earlier than ever before, but ... as well as identify those more likely to develop cancer ... cancer detection, so helping to save peoples, lives," said Diana ...
(Date:9/30/2014)... HealthDay Reporter , MONDAY, ... given broad-spectrum antibiotics before the age of 2 may ... childhood, new research suggests. Broad-spectrum antibiotics target a ... the study. "It is a reason to think ... are picking," said lead researcher Dr. Charles Bailey, attending ...
(Date:9/30/2014)... 2014 Visit Pam and Steve’s quiet ... you will find a loving couple facing the most ... , Steve was diagnosed with ALS – ... – just before the couple’s second wedding anniversary. ... new video, “Care, Support & ALS,” that’s ...
Breaking Medicine News(10 mins):Health News:Rising Consumption of Meat and Meat Products to Fuel Growth in the Global Feed Acidifiers Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Consumption of Meat and Meat Products to Fuel Growth in the Global Feed Acidifiers Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Genetic test would help 'cut bowel cancer spread' 2Health News:Genetic test would help 'cut bowel cancer spread' 3Health News:New blood test determines whether you have or are likely to get cancer 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2
... brain development, the brains first cells neuroepithelial stem cells ... evolves into the various cells of the fully formed brain. ... critical for these stem cells to divide correctly. Without it, ... offers insight into the first steps of brain development, and ...
... QMed, Inc. (Nasdaq:,QMED) today announced financial results for ... Revenue for the year decreased to,$5,246,789 from $8,136,305 a ... $(0.66) per share on a diluted basis, compared to ... basis the previous year.,Revenue for the three-month period ended ...
... hairdressers, barbers , , WEDNESDAY, March 26 (HealthDay News) -- ... had high concentrations of coloring ingredients appear to be ... new report contends. , The authors said the findings ... -- that hair dyes appear to increase the risk ...
... Emergency Medicine is hosting the 11th annual Society of ... Mesa, Calif. As part of the forum, UC Irvine ... variety of related areas ranging from the continued decline ... computerized alcohol-use counseling. , Emergency department ...
... Aging Specialist to Consult with Award-Winning Mind Fitness ... America Conference,Booth #1317) -- CogniFit, Ltd., the company ... software that will enhance human cognitive,performance and health, ... of,Gloria Cavanaugh, long-time president of the American Society ...
... protein, study says. , , WEDNESDAY, March 26 (HealthDay News) -- Keeping ... because it,s harder for women to replace muscle that,s lost naturally ... of 29 healthy women and men, aged 65 to 80, found ... mass -- a key difference in the way women,s and men,s ...
Cached Medicine News:Health News:Key factor in brain development revealed, offers insight into disorder 2Health News:Key factor in brain development revealed, offers insight into disorder 3Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 2Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 3Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 4Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 5Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 6Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 7Health News:Now-Banned Hair Dyes Linked to Bladder Cancer 2Health News:UC Irvine researchers present latest findings at emergency medicine forum 2Health News:CogniFit to Work With Gloria Cavanaugh, Former ASA President 2Health News:Older Women Have Harder Time Preserving Muscle Than Men 2
(Date:9/30/2014)... Sept. 30, 2014  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) ... the post-approval study of its NeuRx DPS® System ... meet the FDA enrollment requirement was implanted over ... The NeuRx DPS®, which is the only medical ... patients, is a humanitarian device that obtained approval ...
(Date:9/30/2014)... Sept. 30, 2014  eHealth, electronic access of ... access of this information, has become a major ... that has not translated into user-friendly, effective products. ... - http://photos.prnewswire.com/prnh/20140929/149123 For ... years developing MWD® Health Manager iEHR, a multilingual ...
(Date:9/30/2014)... Sept. 30, 2014 It is evident from the ... is not performing upto expectations due to the lack of ... with the intake of omega-3 fatty acids. Among omega-3 ingredient ... fish oil, attributed to the large vegetarian population in ... polyunsaturated fatty acid (PUFAs) ingredients is in growth stage of ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... The 2009 Frost & Sullivan European Medical ... the radiology applications market is conferred on Viatronix ... the diagnostic imaging space. , (Logo: ... Viatronix has shown dedication to both developing and ...
... PAC, a leading global provider of advanced analytical instruments ... of the ANTEK MultiTek(TM) testing system for the fast, ... and halides. Industries include BioFuels, Chemicals, Food & Beverage, ... , "MultiTek(TM) is the only instrument on the ...
Cached Medicine Technology:Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 2Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 3Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 4New ANTEK MultiTek(TM) by PAC Provides Fast, All-in-One Testing for Sulfur, Nitrogen, Halides 2
... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: